TransCon PTH (palopegteriparatide) is an investigational once‐daily prodrug with sustained release of active PTH in development as a treatment for adults with hypoparathyroidism.(19, 20) TransCon PTH consists of a parent drug, PTH(1‐34), transiently conjugated to a branched methoxypolyethylene glycol (mPEG) carrier through a proprietary linker. Here, PTH is linked to hypoparathyroidism.